JWM
CORT icon

JPL Wealth Management’s Corcept Therapeutics CORT Stock Holding History

JPL Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31K Buy
38
+18
+90% +$1.09K ﹤0.01% 900
2026
Q1 		$807 Buy
+20
New +$748 ﹤0.01% 1264
2025
Q4 		– Sell
-20
Closed -$1.66K – 326
2025
Q3 		$1.66K Buy
+20
New +$1.45K ﹤0.01% 901

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JPL Wealth Management's CORT Position: Q2 2026 in Review

JPL Wealth Management increased its Corcept Therapeutics (CORT) stake by 90% in Q2 2026, buying an estimated $1.09K and bringing the position to 38 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #900.

JPL Wealth Management first reported a position in CORT in Q3 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • JPL Wealth Management held 38 shares of Corcept Therapeutics worth $3.31K as of Q2 2026.
  • JPL Wealth Management bought 18 Corcept Therapeutics shares in Q2 2026, an estimated $1.09K.
  • Corcept Therapeutics made up ﹤0.01% of JPL Wealth Management's portfolio in Q2 2026, its #900 holding.
  • JPL Wealth Management first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.